Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sandoz
Prospective, open label, non-comparative, multicenter study. Short children born SGA were to be treated until they reached final height, but treatment could be discontinued earlier if medically indicated or if there was inadequate response to treatment.
Age
4–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pre-pubertal (Tanner stage I) children born SGA Boys: 4 years of age or older Girls: 4 years of age or older
Growth disturbance defined as current height SDS \< -2.5 (and parental adjusted SDS \<-1) for chronological age and sex according to country specific references.
Birth weight and/or length below -2 standard deviations (SD) for gestational age
You may not be if
Onset of puberty
Closed epiphyses
Diabetes mellitus type I or type II
Fasting blood glucose greater than 100 mg/dl or greater than 5.6 mmol/l measured in venous blood sample
Abnormal findings in Oral Glucose Tolerance Test (OGTT) defined by greater than 140 mg/dl or greater than 7.8 mmol/l after 120 minutes
Known IGF-I level above +2SD for sex and age
Acute critical illness
Previous treatment with any hGH preparation
Treatment with antidiabetic medication (e.g. metformin, insulin)